Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcer
Open Access
- 12 February 2007
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 25 (8) , 907-912
- https://doi.org/10.1111/j.1365-2036.2007.03274.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysisBMJ, 2005
- Prospective study of acute gastrointestinal bleeding attributable to anti-inflammatory drug ingestion in the Yorkshire region of the United KingdomPublished by Oxford University Press (OUP) ,2005
- National Trends in Cyclooxygenase-2 Inhibitor Use Since Market ReleaseArchives of internal medicine (1960), 2005
- COX‐2‐selective inhibitors and the risk of upper gastrointestinal bleeding in high‐risk patients with previous gastrointestinal diseases: a population‐based case–control studyAlimentary Pharmacology & Therapeutics, 2004
- The gastrointestinal effects of nonselective NSAIDs and COX-2–selective inhibitors☆Seminars in Arthritis and Rheumatism, 2002
- Promotion of Prescription Drugs to ConsumersNew England Journal of Medicine, 2002
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1999
- The Treatment ofHelicobacter pyloriInfection in the Management of Peptic Ulcer DiseaseNew England Journal of Medicine, 1995